Symptoms & Diagnostic Challenges: The Great Mimicker
At a Glance
Post-transplant lymphoproliferative disease (PTLD) is difficult to diagnose because its symptoms—like fever, fatigue, and organ dysfunction—often mimic infections or transplant rejection. A tissue biopsy is the only definitive way to confirm PTLD, even if EBV blood tests are negative.
Identifying PTLD can be an incredibly frustrating process because it is a “great mimicker.” Its symptoms often look exactly like common post-transplant complications, such as an infection or even the body’s attempt to reject the new organ [1][2].
Common Symptoms: Vague and Specific
PTLD does not have a single “classic” look. Instead, it presents in two main ways: general “B-symptoms” and site-specific symptoms [3].
General “B-Symptoms”
These are whole-body symptoms that can feel like a lingering flu [3]. If you or your child experience any of these symptoms, contact your transplant team immediately—do not wait for your next scheduled appointment.
- Fever and Night Sweats: Persistent, unexplained fevers or waking up drenched in sweat [1].
- Weight Loss: Losing weight without trying [3].
- Fatigue: Deep, overwhelming exhaustion that doesn’t improve with rest [3].
Site-Specific Symptoms
Often, PTLD grows in a specific part of the body, causing symptoms related to that area [3]:
- The Transplanted Organ (Allograft): You may experience pain, tenderness, or a decline in organ function (e.g., rising creatinine in a kidney transplant) [4][5].
- Gastrointestinal (GI) Tract: Abdominal pain, nausea, vomiting, or even bleeding [6].
- Central Nervous System (CNS): New headaches, seizures, confusion, or trouble walking [7][8].
- Lymph Nodes: Swollen, painless “lumps” in the neck, armpits, or groin [9].
The Diagnostic “Triple Threat”
Doctors often struggle to diagnose PTLD quickly because it is frequently confused with three other conditions [1][10]:
- Acute Cellular Rejection (ACR): The most common pitfall. Both PTLD and rejection can cause fever and organ failure. In fact, PTLD and rejection can sometimes happen at the same time in the same organ [11].
- Opportunistic Infections: Common viruses like CMV (Cytomegalovirus) cause nearly identical symptoms to PTLD [2].
- Inflammation: General inflammation or other autoimmune issues can mimic the “hot spots” seen on imaging [12].
Why Blood Tests Aren’t Always Enough
A common misconception is that if the EBV viral load in your blood is low or negative, you don’t have PTLD. This is not always true [9].
- Localized Disease: Sometimes the PTLD is tucked away in one specific organ or the brain, and the virus hasn’t spilled over into the bloodstream in large amounts [9][13].
- EBV-Negative PTLD: About 20–30% of PTLD cases are “EBV-negative,” meaning the virus isn’t the main driver. In these cases, the blood test will always be negative [14][15].
Because of this, a tissue biopsy remains the only definitive way to confirm PTLD [9].
The Role of PET/CT Scans
A PET/CT scan is a powerful tool used to find PTLD throughout the body [16]. It uses a radioactive sugar “tracer” to find areas of high activity (hot spots) [17].
- The Benefit: It helps doctors see the full “burden” of the disease and tells them the best place to perform a biopsy [18][17].
- The Limitation: PET scans are sensitive but not specific. This means they are great at finding something wrong, but they can’t tell the difference between PTLD, a simple infection (like TB or pneumonia), or post-surgical inflammation [12][19].
Early-Onset vs. Late-Onset
The timing of your symptoms matters. Early-onset PTLD (usually within the first year) is almost always linked to EBV and often involves the transplanted organ [20][21]. Late-onset PTLD (occurring years later) is more likely to be EBV-negative and behaves more like a traditional lymphoma [22][23]. Regular, lifelong monitoring is essential because the risk never fully disappears [24][25].
Common questions in this guide
Why is PTLD hard to diagnose?
Does a negative EBV blood test mean I don't have PTLD?
What are the 'B-symptoms' of PTLD?
Can I have PTLD and organ rejection at the same time?
Why do doctors use a PET scan if it can't definitively diagnose PTLD?
Get notified when new evidence is published on Post-transplant lymphoproliferative disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (25)
- 1
Posttransplant Lymphoproliferative Disorder Status Post-Solid Organ Transplant Presenting to the Emergency Department: Single Institute Experience.
Rao S, Smith DA, Kikano EG, et al.
Journal of computer assisted tomography 2021; (45(6)):894-903 doi:10.1097/RCT.0000000000001212.
PMID: 34347710 - 2
Clinical analysis of malignant lymphoma secondary to transplantation: the notorious lymphoproliferative disease.
Yan Z, Wang H, Liu Y, et al.
American journal of translational research 2023; (15(11)):6632-6643.
PMID: 38074803 - 3
COVID-19 and Superimposed Aspergillosis in a Dual Organ Recipient with Diagnosed B-Cell Lymphoproliferative Disorder: A Rare Case Report and Literature Review.
Karadžić-Ristanović V, Pavlović J, Brković V, et al.
Diseases (Basel, Switzerland) 2025; (13(10)) doi:10.3390/diseases13100339.
PMID: 41149073 - 4
Intussusception Can Be the First Sign of Post-transplant Lymphoproliferative Disease.
Atici SD, Arican C, Avci EK, et al.
Transplantation proceedings 2019; (51(4)):1184-1186 doi:10.1016/j.transproceed.2019.01.085.
PMID: 31101196 - 5
[Primary central nervous system post-transplant lymphoproliferative disorder with few specific abnormal findings observed on MRI and in the cerebrospinal fluid].
Takeuchi Y, Ochiai J, Onoda O, et al.
Rinsho shinkeigaku = Clinical neurology 2022; (62(1)):44-48 doi:10.5692/clinicalneurol.cn-001677.
PMID: 34924473 - 6
[A case of primary central nervous system post-transplant lymphoproliferative disease 14 years after living donor liver transplantation].
Otsuka H, Shima T, Yoshida K, et al.
Rinsho shinkeigaku = Clinical neurology 2024; (64(11)):794-801 doi:10.5692/clinicalneurol.cn-001991.
PMID: 39428512 - 7
Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings.
Hoyt D, Hughes J, Liu J, Ayyad H
Radiology case reports 2024; (19(6)):2168-2182 doi:10.1016/j.radcr.2024.02.030.
PMID: 38515768 - 8
Primary Central Nervous System Posttransplant Lymphoproliferative Disorder After Kidney Transplant.
Stone T, Eskandari R, Baker T, et al.
Journal of pediatric hematology/oncology 2021; (43(4)):144-146 doi:10.1097/MPH.0000000000001818.
PMID: 32398602 - 9
Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H, Itonaga H, Taguchi J, et al.
Leukemia research reports 2019; (11()):27-30 doi:10.1016/j.lrr.2019.04.003.
PMID: 31049285 - 10
Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study.
Lückemeier P, Radujkovic A, Holtick U, et al.
Frontiers in oncology 2023; (13()):1208028 doi:10.3389/fonc.2023.1208028.
PMID: 37427100 - 11
Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum.
Mishra A, Kubina M, Peddu DK, et al.
Case reports in gastrointestinal medicine 2025; (2025()):1627234 doi:10.1155/crgm/1627234.
PMID: 41200208 - 12
Extrapulmonary Tuberculosis Mimicking Malignancy.
Güneren C, Uslu Beşli RL, Sayman HB
Molecular imaging and radionuclide therapy 2025; doi:10.4274/mirt.galenos.2025.43925.
PMID: 41414703 - 13
Epstein Barr Virus Quantitative Polymerase Chain Reaction Monitoring in Lung and Bone Marrow Transplant Patients to Predict Post-Transplant Lymphoproliferative Disorder: A Systematic Review.
Divithotawela C, Lee SZ, Schulz M, Chambers DC
Transplantation proceedings 2025; (57(5)):931-939 doi:10.1016/j.transproceed.2025.03.008.
PMID: 40316451 - 14
A Case of Epstein-Barr Virus-Negative Post-transplant Lymphoproliferative Disorder in a Solid Organ Transplant Recipient With Untreated Chronic Hepatitis C.
Asiimwe E, Mead M
Cureus 2024; (16(1)):e53323 doi:10.7759/cureus.53323.
PMID: 38435861 - 15
Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient.
Lee C, Vincentelli H, Visuri J, et al.
Cureus 2021; (13(9)):e18134 doi:10.7759/cureus.18134.
PMID: 34567913 - 16
18F-FDG PET/CT is an ideal imaging modality for the early diagnosis of relapsing polychondritis: A case report.
Wang J, Liu X, Pu C, Chen Y
Medicine 2017; (96(30)):e7503 doi:10.1097/MD.0000000000007503.
PMID: 28746194 - 17
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan in an Unusual Case of Lymphoma with Secondary Involvement of Uterine Cervix Presenting as a Pathological Fracture.
Sasikumar A, Joy A, Pillai MR, Thomas B
Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2017; (32(1)):54-56 doi:10.4103/0972-3919.198483.
PMID: 28242988 - 18
FDG-PET/CT and Auricular Cartilage Biopsy Are Useful for Diagnosing with Relapsing Polychondritis in Patients without Auricular Symptoms.
Okuda S, Hirooka Y, Itami T, et al.
Life (Basel, Switzerland) 2021; (11(9)) doi:10.3390/life11090956.
PMID: 34575105 - 19
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis.
Zhao M, Xin XF, Hu H, et al.
Translational lung cancer research 2019; (8(3)):208-213 doi:10.21037/tlcr.2019.06.09.
PMID: 31367534 - 20
The promise of a prophylactic Epstein-Barr virus vaccine.
Balfour HH, Schmeling DO, Grimm-Geris JM
Pediatric research 2020; (87(2)):345-352 doi:10.1038/s41390-019-0591-5.
PMID: 31641280 - 21
Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study.
Walti LN, Mugglin C, Sidler D, et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2021; (21(7)):2532-2542 doi:10.1111/ajt.16423.
PMID: 33289340 - 22
Subtype-specific progression of post-transplant lymphoproliferative disease (PTLD) in children: Implications for age-based surveillance and early intervention strategies.
Wang S, Zong Z, Li L, et al.
Transplant immunology 2025; (93()):102321 doi:10.1016/j.trim.2025.102321.
PMID: 41167402 - 23
T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review.
Jiang C, Huang J, Shao J, et al.
Cell transplantation 2024; (33()):9636897241259722 doi:10.1177/09636897241259722.
PMID: 38856035 - 24
Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan.
Ishihara H, Shimizu T, Unagami K, et al.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2016; (20(2)):165-73 doi:10.1111/1744-9987.12392.
PMID: 26948427 - 25
Clinical characteristics and outcomes of PTLD following intestinal transplantation.
Wozniak LJ, Mauer TL, Venick RS, et al.
Clinical transplantation 2018; (32(8)):e13313 doi:10.1111/ctr.13313.
PMID: 29888807
This page provides educational information about PTLD symptoms and diagnostic challenges. Always consult your transplant team to evaluate any new symptoms or medical concerns.